Below are the financial statements of Edgewise Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in thousands of USD | 2024 as of 2024-12-31 | 2023 as of 2023-12-31 |
|---|---|---|
| Assets | — | — |
| Current assets | — | — |
| Cash and cash equivalents | 41,666a | 86,097a |
| Marketable securities, available for sale | 428,504a | 232,296a |
| Prepaid expenses and other assets | 5,313a | 8,604a |
| Total current assets | 475,483a | 326,997a |
| Property and equipment, net | 9,503a | 10,443a |
| Operating lease right-of-use asset | 1,569a | 2,247a |
| Other non-current assets | 262a | 348a |
| Total assets | 486,817a | 340,035a |
| Liabilities and stockholders' equity | — | — |
| Current liabilities | — | — |
| Accounts payable | 5,579a | 4,025a |
| Accrued compensation | 10,056a | 5,695a |
| Accrued other expenses | 7,229a | 6,071a |
| Operating lease liability, current portion | 996a | 980a |
| Total current liabilities | 23,860a | 16,771a |
| Operating lease liability, net of current portion | 3,741a | 4,434a |
| Total liabilities | 27,601a | 21,205a |
| Stockholders' equity | — | — |
| Preferred stock | 0a | 0a |
| Common stock | 9a | 7a |
| Additional paid-in capital | 837,363a | 563,487a |
| Accumulated other comprehensive income | 420a | 99a |
| Accumulated deficit | -378,576a | -244,763a |
| Total stockholders' equity | 459,216a | 318,830a |
| Total liabilities and stockholders' equity | 486,817a | 340,035a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Edgewise Therapeutics’s data sources below and access millions more through our Disclosure Search.